Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2024, were $14.4 million, compared to $14.2 million for the same period in 2023. The increase was due ...
An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...
Turnstone Biologics (TSBX) announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the ...
SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel ...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...
Researchers found that tumor-infiltrating lymphocyte (TIL) density may play an important role in predicting the response to combining immunotherapy with chemotherapy. According to study findings ...
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect ...
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
uk.investing.com on MSN14d
Lyell shares down as BofA double downgrades to SellShares of Lyell Immunopharma Inc (NASDAQ:LYEL) fell around 4% Wednesday after Bank of America (NYSE:BAC) analysts double downgraded the stock from Buy to Underperform and slashed their price objective ...
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback